Consorci Sanitari Del Maresme

At Consorci Sanitari Del Maresme, researchers are evaluating innovative approaches to lower the risk of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease. The goal is to improve long‑term survival by testing novel agents and treatment strategies.

• Prevention of major adverse cardiovascular events in high‑risk populations
• Assessment of new lipid‑modifying therapies
• Safety profiling of cardiovascular drugs in older adults

These studies aim to provide safer, more effective options for individuals at risk of heart attacks, strokes, and related complications.

Clinical investigations at the site target improved outcomes for ulcerative colitis and complex gastrointestinal surgeries, such as total gastrectomy for cancer. Researchers are also testing techniques to reduce anastomotic leaks and to speed recovery after urgent cholecystectomy.

• Reducing esophagojejunal anastomosis dehiscence in cancer surgery
• Evaluating discontinuation strategies for ulcerative colitis remission
• Assessing indocyanine green fluorescence to shorten cholecystectomy time

The overarching purpose is to enhance surgical safety and provide better disease control for digestive disorders.

The department conducts trials focused on acute infections of the male urinary tract, including acute bacterial prostatitis. Studies compare antibiotic regimens and measure rapid symptom relief and clinical cure.

• Comparative efficacy of oral antibiotics for prostatitis
• Time to resolution of urinary symptoms after treatment
• Safety assessment of short‑course therapy in male patients

These efforts aim to optimize therapy while minimizing side effects for men affected by urogenital infections.

Researchers are addressing persistent pain after common surgical procedures, such as inguinal hernia repair. The focus is on preventing chronic postsurgical pain through peri‑operative medication strategies.

• Evaluating duloxetine for reduction of chronic postoperative pain
• Identifying patients at high risk for long‑term pain
• Assessing safety of pain‑prevention protocols

By limiting chronic pain development, the trials seek to improve quality of life after musculoskeletal surgery.

The oncology unit leads a broad portfolio of cancer studies, covering breast cancer, non‑small cell lung cancer, and colorectal cancer. Trials test targeted therapies, immunotherapy combinations, and new sequencing approaches to increase survival and reduce recurrence.

• Comparing HER2‑targeted antibody‑drug conjugates in high‑risk breast cancer
• Adjuvant immunotherapy for early‑stage triple‑negative breast cancer
• Sequencing of biologic agents with chemotherapy in metastatic colorectal cancer
• Evaluation of RET‑fusion inhibitors in advanced lung cancer

The aim is to bring more effective, personalized treatments to patients across multiple tumor types.

Trials in this area focus on severe psychiatric conditions, especially schizophrenia and first‑episode psychosis. Researchers are identifying biomarkers and comparing antipsychotic agents to improve response and reduce discontinuations.

• Multi‑omics biomarker discovery for treatment response
• Comparative efficacy of aripiprazole versus paliperidone
• Long‑term adherence and relapse prevention strategies

The overarching goal is to personalize therapy and enhance outcomes for individuals living with mental illness.

The site investigates therapies for lung malignancies, including early and advanced non‑small cell lung cancer. Studies assess the addition of immunotherapy to standard chemotherapy and explore novel targeted agents for specific genetic alterations.

• Neoadjuvant atezolizumab combined with chemotherapy for resectable disease
• Selpercatinib versus placebo in RET‑fusion positive NSCLC
• Adjuvant pembrolizumab analogues after surgical resection

These efforts aim to increase event‑free survival and reduce disease recurrence in lung cancer patients.

Research includes innovative diagnostic tools that enhance visualization of the biliary tree, such as indocyanine green fluorescence cholangiography. The objective is to improve intra‑operative decision‑making and lower complication rates.

• Assessment of fluorescence imaging in acute cholecystitis surgery
• Measurement of operative time reduction with ICG guidance
• Safety evaluation of intra‑operative dye use

By refining physiological monitoring, the trials support safer surgical practices for digestive conditions.

Beyond schizophrenia, the institution conducts studies on broader mental disorders, seeking to improve diagnostic accuracy and treatment effectiveness through biomarker integration and patient‑reported outcomes.

• Development of predictive panels for antipsychotic response
• Evaluation of quality‑of‑life measures during therapy
• Comparison of standard versus biomarker‑guided treatment pathways

The aim is to move toward precision psychiatry, offering tailored interventions for diverse mental health conditions.

A subset of studies at the centre spans multiple therapeutic areas, integrating oncology, cardiology, and gastroenterology to address complex patient needs. These interdisciplinary trials test combined regimens and holistic care models.

• Cross‑disciplinary safety monitoring for combined cancer‑cardio therapies
• Evaluation of integrated care pathways for patients with comorbid conditions
• Health‑economic analyses of multi‑modal treatment strategies

Such research reflects the site’s commitment to comprehensive, patient‑centered innovation.